Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
Research Study Number | 9816 |
Principal Investigator | Masumi Ueda Oshima |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | 9816 |
Contact | Seattle Cancer Care Alliance Intake Office |
Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Leukemia, Acute Lymphoblastic (ALL); Leukemia, Acute Myeloid (AML); Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Lymphoma, Hodgkin; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Multiple Myeloma (MM); Myelodysplastic Syndromes (MDS); Lymphoma, Non-Hodgkin (NHL); Leukemia, Myeloid; Leukemia, Lymphoid; Immunoproliferative Disorders; Hematopoietic Cell Transplantation (HCT); Myeloproliferative Disorders (MPD); Myelodysplastic-Myeloproliferative Diseases; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Prolymphocytic; Bone Marrow Diseases; Leukemia, Chronic Myelogenous; Neoplasms, Plasma Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases; Plasma Cell Myeloma; Hematologic Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.